(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid.



Latest News

Reuters: Hearing in Russia curler case canceled, says CAS

Reuters: Explosive device thrown at U.S. embassy building in Montenegro

USA Today: The Latest: US puts Rooney in net for gold medal hockey game

USA Today: Vonn leads, Shiffrin in mix after downhill leg of combined

USA Today: Wake Forest keeps Pittsburgh winless in ACC 63-57

USA Today: How U.S. hockey team could look if NHL goes to 2022 Winter Olympics

Daily Mail: Explosive device thrown at U.S. embassy building in...

Daily Mail: Germany suspends visas for Cambodian govt members over...

ABC: Vonn leads, Shiffrin in mix after downhill leg of combined

Times of Israel: Nazi hunter group weighs travel warning for Poland over Holocaust law

Daily Mail: Schmaltz scores in 7th round of SO, Blackhawks edge...

Daily Mail: They're right, Chengdu is not just pandas

Daily Mail: North Qld nursing home hires nurse adviser

Daily Mail: British bomb found in Sydney Harbour

Daily Mail: NT child protection system 'in crisis'

Daily Mail: Cambodian prime minister will 'beat up' Sydney protestors

Los Angeles Times: Kings trade Darcy Kuemper to Coyotes for Tobias Rieder and Scott Wedgewood

CNBC: Australian prime minister to bring up China, Trans-Pacific trade deal during Trump talks

FOX: Billy Graham dies: 'America's Pastor,' adviser to presidents

CNN: Survivor to Rubio: 'Why do we have to march ... to save innocent lives?'

ABC: Geraldo Rivera talks weapons age-limits with Trump

Daily Mail: Mother sheds 60 kilos without exercise

Jpost: Explosive device thrown at U.S.embassy building in Montenegro